NASDAQ:ALT Altimmune (ALT) Stock Price, News & Analysis $2.73 -0.03 (-1.09%) Closing price 10/2/2026 04:00 PM EasternExtended Trading$2.76 +0.03 (+1.06%) As of 10/2/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Altimmune Stock (NASDAQ:ALT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Altimmune alerts:Sign Up Key Stats Today's Range$2.71▼$2.8150-Day Range$2.73▼$3.4252-Week Range$2.56▼$6.44Volume4.24 million shsAverage Volume3.68 million shsMarket Capitalization$531.04 millionP/E RatioN/ADividend YieldN/APrice Target$14.33Consensus RatingModerate Buy Company Overview Altimmune, Inc. (NASDAQ:ALT) is a clinical-stage biotechnology company developing peptide-based therapeutics for metabolic and liver diseases. The company’s lead product candidate is pemvidutide, an investigational dual GLP-1 and glucagon receptor agonist being studied for chronic weight management and metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH). Altimmune’s development programs are focused on addressing obesity, related metabolic conditions and chronic liver disease. Pemvidutide is designed to combine effects on appetite, body weight and metabolic health, and the company evaluates its potential through clinical studies. As an investigational medicine, its safety and effectiveness remain subject to ongoing clinical research and regulatory review. Headquartered in Gaithersburg, Maryland, Altimmune conducts its research and development activities primarily through clinical programs and collaborations supporting the advancement of its therapeutic candidates. The company is led by Vipin K. Garg, Ph.D., who serves as president and chief executive officer.AI Generated. May Contain Errors. Read More Altimmune Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks38th Percentile Overall ScoreALT MarketRank™: Altimmune scored higher than 38% of companies evaluated by MarketBeat, and ranked 655th out of 887 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingModerate Buy Consensus RatingAltimmune has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on no strong buy ratings, 8 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialAltimmune has a consensus price target of $14.33, representing about 425.0% upside from its current price of $2.73.Amount of Analyst CoverageAltimmune has only been the subject of 3 research reports in the past 90 days.Read more about Altimmune's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Altimmune are expected to grow in the coming year, from ($0.58) to ($0.54) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Altimmune is -3.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Altimmune is -3.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAltimmune has a P/B Ratio of 1.37. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Altimmune's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted27.04% of the float of Altimmune has been sold short.Short Interest Ratio / Days to CoverAltimmune has a short interest ratio ("days to cover") of 15.38, which indicates bearish sentiment.Change versus previous monthShort interest in Altimmune has recently increased by 4.09%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAltimmune does not currently pay a dividend.Dividend GrowthAltimmune does not have a long track record of dividend growth. News and Social Media1.8 / 5News Sentiment-0.18 News SentimentAltimmune has a news sentiment score of -0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Altimmune this week, compared to 5 articles on an average week.Search InterestOnly 11 people have searched for ALT on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows9 people have added Altimmune to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Altimmune insiders have not sold or bought any company stock.Percentage Held by Insiders1.60% of the stock of Altimmune is held by insiders.Percentage Held by Institutions78.05% of the stock of Altimmune is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Altimmune's insider trading history. Receive ALT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Altimmune and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ALT Stock News HeadlinesAltimmune consensus price target increased by 16.59% to MX$328.821 hour ago | msn.comAltimmune no Stifel 2026 Virtual Cardiometabolic Forum: aposta no fígadoSeptember 30, 2026 | br.investing.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.October 4 at 1:00 AM | Porter & Company (Ad)Altimmune en el Foro Virtual Cardiometabólico Stifel 2026: apuesta por el hígadoSeptember 30, 2026 | mx.investing.comAltimmune, Inc. Announces Appointment of Richard Menziuso as Global Controller and Principal Accounting Officer, Effective September 29, 2026September 30, 2026 | marketscreener.comMAltimmune, Inc. (NASDAQ:ALT) Stock Rated "Moderate Buy" by Sell-Side AnalystsSeptember 25, 2026 | americanbankingnews.comAltimmune’s Phase 3 MASH Trial Puts Pemvidutide in the Spotlight for InvestorsSeptember 23, 2026 | tipranks.comAltimmune to Participate in Stifel Cardiometabolic ForumSeptember 23, 2026 | globenewswire.comSee More Headlines ALT Stock Analysis - Frequently Asked Questions How have ALT shares performed this year? Altimmune's stock was trading at $3.61 at the beginning of the year. Since then, ALT stock has decreased by 24.4% and is now trading at $2.73. How were Altimmune's earnings last quarter? Altimmune, Inc. (NASDAQ:ALT) issued its earnings results on Wednesday, August, 12th. The company reported ($0.12) earnings per share for the quarter, beating analysts' consensus estimates of ($0.14) by $0.02. Read the conference call transcript. When did Altimmune's stock split? Shares of Altimmune reverse split on Friday, September 14th 2018.The 1-30 reverse split was announced on Thursday, September 13th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, September 13th 2018. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. How do I buy shares of Altimmune? Shares of ALT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Altimmune own? Based on aggregate information from My MarketBeat watchlists, some other companies that Altimmune investors own include Invesco QQQ (QQQ), Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Pfizer (PFE) and SPDR S&P 500 ETF Trust (SPY). Company Calendar Last Earnings8/12/2026Today10/04/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (5m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 ALT's financial health is in the Red zone, according to TradeSmith. ALT has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ALT CIK1326190 Webaltimmune.com Phone(240) 654-1450Fax410-269-2601Employees57Year Founded1997Price Target and Rating Average Price Target for Altimmune$14.33 High Price Target$20.00 Low Price Target$10.00 Potential Upside/Downside+425.0%Consensus RatingModerate Buy Rating Score (0-4)2.70 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($0.78) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$88.09 million Net MarginsN/A Pretax Margin-296,000.00% Return on Equity-31.41% Return on Assets-26.96% Debt Debt-to-Equity Ratio0.07 Current Ratio26.78 Quick Ratio26.78 Sales & Book Value Annual Sales$40 thousand Price / Sales13,275.99 Cash FlowN/A Price / Cash FlowN/A Book Value$1.99 per share Price / Book1.37Miscellaneous Outstanding Shares194,520,000Free Float191,406,000Market Cap$531.04 million OptionableOptionable Beta0.06 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:ALT) was last updated on 10/4/2026 by MarketBeat.com Staff. From Our PartnersElon Warns "America Will Go Bankrupt". Trump's Plan Inside.National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...American Hartford Gold | SponsoredWATCH THIS BEFORE DECEMBER 8th!!James Altucher says a quiet government filing could reveal Elon Musk's biggest move yet, and almost nobody has...Paradigm Press | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredI'm giving you a space stock today. Free.On December 8th, $600 billion in frozen SpaceX stock comes loose. Dylan Jovine says one simple purchase in any...Behind the Markets | SponsoredA new kind of civil war is coming after election day?Across America, AI-driven backlash is fueling protests, lawsuits, and moratoria that could reshape the politic...Stansberry Research | SponsoredHow Elon’s Empire Ends (and how to profit)Marc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg termi...Chaikin Analytics | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Altimmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Altimmune With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
